Taysha Gene Therapies, Inc. (TSHA) Operating cash flow 2020–2025
Taysha Gene Therapies, Inc. (TSHA) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$93.1MFY2025 · since FY2020: -$30.7M → -$93.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$93.1M | -14.6% |
| FY2024 | -$81.2M | -11.2% |
| FY2023 | -$73.0M | +17.4% |
| FY2022 | -$88.4M | +24.5% |
| FY2021 | -$117.0M | -280.9% |
| FY2020 | -$30.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TSHA financial trends
TSHA RevenueTSHA Net incomeTSHA Net marginTSHA Gross profitTSHA Gross marginTSHA Operating incomeTSHA Operating marginTSHA Free cash flowTSHA Capital expendituresTSHA Return on equityTSHA Stock buybacksTSHA Dividends paidTSHA Total assetsTSHA Total liabilitiesTSHA Shareholders’ equityTSHA overview →